loader2
Partner With Us NRI

Ami Organics Ltd

Company details

857.50
899.55
764.15
1,182.40
6M Return -15.51%
1Y Return -13.92%
Mkt Cap.(Cr) 3,187.51
Volume 11,466
Div Yield 0.35%
OI
-
OI Chg %
-
Volume 11,466

Open Free Demat Account Online with ICICIDIRECT

Ami Organics Ltd.

Q2FY23 Quarterly Result Announced for Ami Organics Ltd.

Pharmaceutical company Ami Organics announced Q2FY23 Results:

  • Revenue from operations for Q2FY23 grew by 20.2% YoY to Rs 1,470 million; sequentially revenue grew by 12.2%
  • The gross margins for the quarter were at 48.0%, compared to 54.0% in Q2FY22 and 48.8% in Q1FY23
  • EBITDA for the quarter came at Rs 281 million, up 2.8% YoY compared to Rs 274 million in Q2FY22 and up 18.8% on a sequential basis compared to Rs 237 million in Q1FY23
  • EBITDA margins for the quarter were at 19.1%, compared to 22.4% in Q2FY22 and 18.1% in Q1FY23. We have been able to improve our EBITDA margin on a sequential basis due to improvements in operating expenses, whereas, lower EBITDA margins of the Specialty Chemical business continue to put pressure on consolidated EBITDA margins
  • PAT for the quarter was at Rs 190 million, up 9.0% YoY. The PAT margins for the quarter were at 13.0%, compared to 14.3% in Q2FY22 and 11.3% in Q1FY23

Naresh Patel, Executive Chairman & Managing Director, Ami Organics Limited, said: “We continue our robust trajectory with 20% YoY growth during Q2, primarily driven by a significant increase in the advanced pharmaceutical intermediate business, which grew by 25% YoY. That said, the company witnessed a flattish growth in the speciality chemicals business. Our margins continue to strengthen as we keep tight control on cost and because of lower freight rates. I believe margins will continue to see the improvement in coming quarters.

I am delighted to announce that we have successfully developed Methyl Salicylate using flow technology, which is expected to be commercialised from Q3 onwards. This shift in manufacturing technology has resulted in a considerable reduction in production time, 3x capacity expansion, and cost savings of around 5-7%.

Electrolyte additives continue to see good inquiries from clients across the globe and we expect to commercialise the product before the end of FY23.

Overall, I remain optimistic about our business growth in the coming quarters and years on the back of various strong growth levers.”

Result PDF

View Other Company Results

FINANCIALS

Sales

Operating Profit

Profit after Tax

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after Tax

PE

Debt/Equity

P BV

COMPARISION

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 522.28 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 17,871.26 -28,732.63
LAST 3M 35,065.84 -30,146.79
LAST 6M 57,360.50 38,576.46
LAST 12M 186,944.70 -113,961.48

NSE Board Meetings Forthcomming

Feb 04, 2023 l NSE Board Meetings Forthcomming

Board Meeting for Today

Feb 04, 2023 l Board Meetings for Today

Ami Organics Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Feb 01, 2023 l NSE Announcement

Date Action Type Ratio
Jul 29, 2022 Dividend 30

INFORMATION

Stock PE (TTM)

42.33

Promoter Holding

39.41%

Book Value

149.4167

ROCE

23.54%

ROE

20.88%

Description

  • The Company was initially formed as a partnership firm in the name of "Ami Organics" with effect from 03 January 2004 at Surat, India. The firm converted into a private limited company under the Companies Act, 1956 under the name of "Ami Organics Private Limited" with a certificate of incorporation dated 12 June 2007. Subsequently, the Company was converted into a public limited company, following which the Company`s name was changed to "Ami Organics Limited", and a fresh certificate of incorporation was issued by RoC on 18 April 2018. The company is one of the leading research and development (R&D) driven manufacturers of specialty chemicals with varied end usage, focussed towards the development and manufacturing of advanced pharmaceutical intermediates for regulated and generic active pharmaceutical ingredients (APIs) and New Chemical Entities (NCE) and key starting material for agrochemical and fine chemicals, especially from the recent acquisition of the business of Gujarat Organics Limited (GOL). As per the F&S Report, the company is one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban. The Pharma Intermediates which the company manufacture, find application in certain high-growth therapeutic areas including anti-retroviral, antiinflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant and anti-coagulant, commanding significant market share both in India and globally. The company`s Pharma Intermediates used for manufacturing of APIs and NCEs portfolio has expanded from over 425 products as of 31 March 2019, to over 450 products as of 31 March 2021. During the FY2021, Bonus shares were issued to the existing shareholders of the Company as on the record date of 31.03.2021 by issue of 2,10,00,000 Equity shares of face value of Rs. 10 each.The Bonus shares were allotted in the ratio of 2:1 i.e Two new equity shares for every one existing shares of the company. As on 31 March 2021,the company has one joint venture company,namely AMI Onco-Theranostics,LLC. During the month of September 2021,the company came out with an IPO which comprised a fresh issue of Rs 200 crore and an offer for sale of Rs 370 crore by shareholders,mopped up a total of Rs 570 crore through its public issue.The company will utilise the proceeds from fresh issue and pre-IPO placement for repaying debts and meeting working capital requirements.The allotted shares were listed on the BSE Ltd and National Stock Exchange of India(NSE) on 14 September 2021.

No Data Found

AGM Date (Month) : Aug
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 543349
NSE Code : AMIORG
Book Closure Date (Month) :
BSE Group : A
ISIN : INE00FF01017

ICICIdirect Ami Organics Ltd FAQ

You can buy Ami Organics Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Ami Organics Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Feb 03, 2023 04:01 PM the closing price of Ami Organics Ltd was ₹ 874.80.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Feb 03, 2023 04:01 PM, the market cap of Ami Organics Ltd stood at ₹ 3,187.51.
The latest PE ratio of Ami Organics Ltd as of Feb 03, 2023 04:01 PM is 42.33
The latest PB ratio of Ami Organics Ltd as of Feb 03, 2023 04:01 PM is 0.17
The 52-week high of Ami Organics Ltd is ₹ 1,182.40 while the 52-week low is ₹ 764.15

Download Our App

market app
market app